IP Library › Granted Patent US 8,946,385
Granted Patent B2
US 8,946,385 · App. 12/525,031 · Granted Feb 3, 2015

Chimeric Fcγ receptor and method for determination of ADCC activity by using the receptor

Inventor: Shigeto Kawai (Tokyo, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha
C07K14/70535C07K16/18G01N33/5014C07K2317/24C07K2317/41C07K2317/732C07K2319/00G01N2500/04C07K2317/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,946,385
App. No.
12/525,031
Granted
Feb 3, 2015
Kind
B2
Abstract

An objective of the present invention is to provide chimeric receptors containing a mouse Fcγ receptor extracellular domain and a human Fcγ receptor transmembrane domain, or chimeric receptors containing a mouse Fcγ receptor extracellular domain and a human γ chain transmembrane domain. Another objective of the present invention is to provide methods for measuring the ADCC activity of mouse antibodies and methods of screening for mouse antibodies having ADCC activity, using the chimeric receptors. To accomplish the above-mentioned objectives, the present inventors produced chimeric molecules by fusing the extracellular domain of mouse FcγR3 or mouse FcγR4 with the transmembrane domain/intracellular domain of human γ chain or human FcγR3, and expressed the chimeric molecules in human NK92 cells. It was revealed that the ADCC activity can be induced by the chimeric receptors produced by any combination of the domains, and that the ADCC activity of mouse antibodies can be measured using the chimeric receptors of the present invention.

Claims (4)

1. A chimeric protein comprising an extracellular domain, a transmembrane domain, and an intracellular domain, wherein the extracellular domain is the extracellular domain of a mouse Fcγ receptor having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, wherein the transmembrane domain is the transmembrane domain of a human Fcγ receptor 3 that has the amino acid sequence of SEQ ID NO: 6, and wherein the intracellular domain is the intracellular domain of a human Fcγ receptor 3 that has the amino acid sequence of SEQ ID NO: 6.

2. A chimeric protein comprising an extracellular domain, a transmembrane domain, and an intracellular domain, wherein the extracellular domain is the extracellular domain of a mouse Fcγ receptor having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, wherein the transmembrane domain is the transmembrane domain of a human γ chain that has the amino acid sequence of SEQ ID NO: 8, and wherein the intracellular domain is the intracellular domain of a human γ chain that has the amino acid sequence of SEQ ID NO: 8.

3. The chimeric protein of claim 1 , wherein the chimeric protein has the amino acid sequence of SEQ ID NO: 10 or 14.

4. The chimeric protein of claim 2 , wherein the chimeric protein has the amino acid sequence of SEQ ID NO: 12 or 16.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2013
From: FORERUNNER PHARMA RESEARCH CO., LTD.
To: CHUGAI SEIYAKU KABUSHIKI KAISHA
Reel/Frame 030998/0288 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2009
From: KAWAI, SHIGETO
To: FORERUNNER PHARMA RESEARCH CO., LTD.
Reel/Frame 023365/0554 →
Priority Claims (1)
JP 2007-020155 · Jan 30, 2007 · national
Continuity (1)
Related Publication 20100035280A1 · Feb 11, 2010